| Previous Close | 35.45 |
| Open | 35.93 |
| Bid | 35.90 x 7000 |
| Ask | 35.91 x 5300 |
| Day's Range | 35.82 - 36.21 |
| 52 Week Range | 29.83 - 36.21 |
| Volume | 12,825,481 |
| Avg. Volume | 17,372,446 |
| Market Cap | 213.69B |
| Beta | 1.06 |
| PE Ratio (TTM) | 26.28 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 1.28 (3.62%) |
| Ex-Dividend Date | 2017-08-02 |
| 1y Target Est | N/A |
- Market Realist•3 minutes ago
Behind Pfizer’s Product Developments after 2Q17
On September 1, 2017, the FDA approved Pfizer's drug Mylotarg (gemtuzumab ozogamicin) for the treatment of CD33-positive acute myeloid leukemia.
- The Wall Street Journal•7 minutes ago
[$$] Murky World of Drug Rebates Gets Airing in Lawsuit
The closely guarded world of drug pricing is getting a public airing in a feud between two of the industry’s biggest companies. The attention drawn to rebates could hurt the profits of some very successful ...
- Barrons.com•12 minutes ago
Pfizer: Is It Time To Buy?
Shares of Pfizer (PFE) have made quite a run in recent weeks. Morgan Stanley’s David Risinger says the drug’s giant’s stock should keep rising, perhaps as high as $44 a share. Earlier today, Risinger upgraded Pfizer from an Equal-weight to an Outperform and set a $39 price target, which is based on a price-to-earnings multiple of 14 times 2018 estimated earnings of $2.76 a share.
